About Treos Bio
Treos Bio is a company based in London (United Kingdom) founded in 2013. Treos Bio has raised $22 million across 2 funding rounds from investors including Luminous Ventures and Isabel Fox. The company has 12 employees as of December 31, 2020. Treos Bio offers products and services including PolyPEPI1018 and PEPI Technology. Treos Bio operates in a competitive market with competitors including Guardant Health, MedGenome, Foundation Medicine, ArcherDX and Natera, among others.
- Headquarter London, United Kingdom
- Employees 12 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Treos Bio Limited
- Date of Incorporation 20 Oct, 2016
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
-$7.06 M (USD)19as on Dec 31, 2018
-
EBITDA
-$7.05 M (USD)19as on Dec 31, 2018
-
Total Equity Funding
$22 M (USD)
in 2 rounds
-
Latest Funding Round
$14 M (USD), Series B
Mar 31, 2021
-
Investors
Luminous Ventures
& 1 more
-
Employee Count
12
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Treos Bio
Treos Bio offers a comprehensive portfolio of products and services, including PolyPEPI1018 and PEPI Technology.
Vaccine for colorectal cancer inducing strong immune responses.
Platform for developing effective peptide-based cancer treatments.
People of Treos Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Treos Bio
Treos Bio has successfully raised a total of $22M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $14 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Treos Bio
Treos Bio has secured backing from 2 investors, including venture fund and angel investors. Prominent investors backing the company include Luminous Ventures and Isabel Fox.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are funded by Luminous Ventures venture capital firm.
|
Locked | Locked | Locked | |
|
IF
Isabel Fox |
Angel investor focusing on Indian startups, with a background in tech and innovation.
|
Locked | Locked | Locked |
Investor details for Treos Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Treos Bio
Investment portfolio details for Treos Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Treos Bio
Detailed financials for Treos Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Treos Bio Comparisons
Peer comparison for Treos Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Treos Bio
Treos Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, MedGenome, Foundation Medicine, ArcherDX and Natera, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of Treos Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Treos Bio
Complete news archive for Treos Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Treos Bio
Treos Bio was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Treos Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Treos Bio is a funded company, having raised a total of $22M across 2 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Treos Bio is 12.
Developer of cancer vaccines and companion diagnostics. Its platform technology uses proprietary algorithms to mine patient genetic profiles and match them to their response to therapeutic vaccines. It has two diagnostic products. The PEPI test is a genetic test that predicts the patients antigen-specific immune response, which in turn can be used to predict the patients response to therapeutic cancer vaccines. The PEPI test is approved as an IVD kit in Europe. The other diagnostic test under development is the Melanoma PEPI Test for identifying high-risk melanoma patients. In addition, the company is developing the PolyPEPI vaccine and companion diagnostic family of products for melanoma, breast cancer, and lung cancer. The companion diagnostics will be used for the biomarker-based stratification of patients.
Treos Bio's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Treos Bio offers PolyPEPI1018 and PEPI Technology.
Treos Bio has 2 investors. Key investors include Luminous Ventures, and Isabel Fox.